TY - JOUR AB - Erlotinib is an oral, small-molecule targeting therapy that inhibits epidermal growth factor tyrosine kinase receptors. Erlotinib has been administered for the treatment of advanced pancreatic cancer and non-small cell lung cancer. In the present trial, erlotinib was administered as second-line monotherapy in pretreated patients with advanced non-small cell lung cancer. Our objectives were to determine response, survival and toxicity. Fifty-four patients pretreated with cisplatin or its analogue-based combinations were evaluated. The disease stage of the patients was IIIB and IV. Thirty-eight patients were male, 16 were female, the median age was 65 years, and the WHO performance status was 0-2. Twenty-five cases were adenocarcinomas, 19 squamous cell carcinomas and 10 were undifferentiated. Erlotinib was administered at a dose of 150 mg daily. In case of intolerable adverse reactions, the dose was either reduced to 100 mg daily or treatment was interrupted for a maximum of two weeks. A partial response was observed in 10 (18.52%) and stable disease in 40 (74.07%) patients. The median time to disease progression was 3 months (95% CI 1.7-10.3), and the median survival was 6 months. Concerning toxicity, 53 patients (98.15%) developed a grade 1-2 skin rash, and 1 (1.85%) grade 3. Diarrhea occurred in 9 (16.67%) patients, nausea and vomiting in 4 (7.41%) and gastritis in 2 (3.70%). The majority of patients tolerated the erlotinib treatment. Of note were the 18.52% response rate and 74.07% stable disease. AD - First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece null AU - Stathopoulos,G.,P. AU - Trafalis,D. AU - Dimitroulis,J. AU - Athanasiou,A. AU - Koutantos,J. AU - Anagnostopoulos,A. DA - 2010/03/01 DO - 10.3892/ol_00000059 EP - 338 IS - 2 JO - Oncol Lett PY - 2010 SN - 1792-1074 1792-1082 SP - 335 ST - Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study T2 - Oncology Letters TI - Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study UR - https://doi.org/10.3892/ol_00000059 VL - 1 ER -